The S&P 500 industrials sector has delivered a robust performance in 2025, with a year to date performance of up +18%. The sector ranked as the third-best-performing sector year to date and, outpacing ...

Q3 2026 Management View William Marshall, Co-Founder, CEO & Chairman of the Board, opened the call by stating, "we generated $81.3 million in revenue, representing approximately 33% growth ...

WASHINGTON, DC — Measures of liver stiffness remained stable or improved in patients with primary biliary cholangitis (PBC) after 36 months of treatment with seladelpar (Livdelzi) based on new data ...

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression – New Data ...

LOS ANGELES--(BUSINESS WIRE)--Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, today announced the closing of a $4.6 ...

BERLIN — A novel investigational ileal bile acid transporter (IBAT) inhibitor, linerixibat, significantly and rapidly reduced cholestatic pruritus in patients with primary biliary cholangitis (PBC), ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. What most interests me is what's available ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary cholangitis (PBC). The pharma—which earned the FDA’s accelerated approval for PBC ...

I wish I had a nickel for every article I've read announcing the “Death of Linear TV.” Is there nonlinear TV? Choose your own adventure programming? No, there’s not. Generally, when someone talks ...